Eplerenone Dosing in Heart Failure with Reduced Ejection Fraction
Start eplerenone at 25 mg once daily in patients with HFrEF, and titrate to the target dose of 50 mg once daily within 4 weeks, provided potassium remains ≤5.0 mEq/L and eGFR is >30 mL/min/1.73 m².
Initial Dosing Based on Renal Function
The starting dose depends critically on kidney function 1, 2, 3:
- eGFR ≥50 mL/min/1.73 m²: Start 25 mg once daily
- eGFR 30-49 mL/min/1.73 m²: Start 25 mg every other day OR 12.5 mg once daily
- eGFR <30 mL/min/1.73 m²: Contraindicated - do not use 3
Critical prerequisite: Serum potassium must be ≤5.0 mEq/L before initiating therapy 1, 2, 3. If potassium is >5.0 mEq/L, eplerenone is contraindicated 3.
Titration Schedule
After initiating at 25 mg daily (or every other day for reduced renal function), titrate to the evidence-based target dose of 50 mg once daily within 4 weeks 4, 3. This target dose was used in the EPHESUS and EMPHASIS-HF trials that demonstrated mortality reduction 5, 6.
For patients with eGFR 30-49 mL/min/1.73 m², the maintenance dose should be 25 mg once daily (not 50 mg) 1, 2.
Potassium-Guided Dose Adjustments
Adjust the dose based on serum potassium levels during treatment 3:
Potassium <5.0 mEq/L:
- Increase from 25 mg every other day → 25 mg daily
- Increase from 25 mg daily → 50 mg daily
Potassium 5.0-5.4 mEq/L:
- No dose adjustment needed
Potassium 5.5-5.9 mEq/L:
- Decrease from 50 mg daily → 25 mg daily
- Decrease from 25 mg daily → 25 mg every other day
- Decrease from 25 mg every other day → withhold temporarily
Potassium ≥6.0 mEq/L:
- Withhold eplerenone immediately
- Restart at 25 mg every other day only when potassium falls to <5.5 mEq/L 3
Monitoring Requirements
The FDA label and guidelines specify rigorous monitoring to prevent life-threatening hyperkalemia 3, 2:
Initial monitoring:
- Check potassium and creatinine before starting therapy
- Recheck at 3-7 days after initiation
- Recheck at 1 week after initiation
- Recheck at 4 weeks (before dose titration)
Ongoing monitoring:
- Monthly for the first 3 months
- Every 3 months thereafter 2
- More frequently if clinical instability, concurrent RAAS inhibitor dose changes, or addition of NSAIDs 5, 2
Critical Safety Considerations
Absolute contraindications 3:
- Serum potassium >5.0 mEq/L at baseline
- eGFR ≤30 mL/min/1.73 m²
- Serum creatinine >2.5 mg/dL (men) or >2.0 mg/dL (women)
- Concurrent strong CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir)
Important drug interactions: If using moderate CYP3A inhibitors (erythromycin, verapamil, fluconazole), do not exceed 25 mg once daily 3.
Discontinue potassium supplements when starting eplerenone, and counsel patients to avoid high-potassium foods and NSAIDs 2.
Clinical Context
The 2022 AHA/ACC/HFSA guidelines give eplerenone a Class 1 recommendation for patients with symptomatic HFrEF and LVEF ≤35% 5. The evidence base includes EPHESUS (post-MI patients) and EMPHASIS-HF (NYHA class II patients), which together demonstrated a 6% relative risk reduction in mortality and 35% reduction in HF hospitalizations 1, 5.
Common pitfall: Real-world hyperkalemia rates (up to 24% in some series) exceed clinical trial rates (1-2%) 7. This occurs when clinicians deviate from strict monitoring protocols or use eplerenone in patients with marginal renal function. The Ontario population study showed tripling of hyperkalemia-related hospitalizations after widespread spironolactone adoption 7. Rigorous adherence to monitoring schedules is not optional—it is essential for safe use.
For patients with eGFR 30-49 mL/min/1.73 m², start conservatively at 25 mg every other day and accept 25 mg daily as the maximum tolerated dose rather than pushing to 50 mg 1, 2.